FDA
-
-
-
-
-
-
-
Vistagen meets ICH safety exposure standards for fasedienol trials
-
-
-
-
-
-
-
Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Me
-
-
-
-
-
-
-
Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder
-
-
-
-
-
-
-
Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update
-
-
-
-
-
-
-
Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference
-
-
-
-
-
-
-
Jefferies Upgrades VistaGen Therapeutics (VTGN) to Buy
-
330,737 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

